Figure S2. Three factors associated with prolonged progression-free survival (PFS) and chemotherapy-free interval (CFI) under olaparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer were identified: BRCA mutant type (A and D), PFI ≥12 months (B and E) and CR to last platinum-based therapy (C and F).

Abbreviations: BRCA, breast cancer susceptibility gene; PARP, poly ADP-ribose polymerase; PFI, platinum-free interval; CR, complete response; PR, partial response; HR, hazard ratios, CI, confidence intervals.